152 related articles for article (PubMed ID: 9933132)
21. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
22. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
[TBL] [Abstract][Full Text] [Related]
23. Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantrone in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Takemura H; Suto H; Kishi S; Urasaki Y; Ueda T
Leuk Res; 2000 Mar; 24(3):249-54. PubMed ID: 10739007
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway.
Pallis M; Russell N
Blood; 2000 May; 95(9):2897-904. PubMed ID: 10779437
[TBL] [Abstract][Full Text] [Related]
25. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance.
Sparrow RL; Hall FJ; Siregar H; Van der Weyden MB
Leuk Res; 1993 Nov; 17(11):941-7. PubMed ID: 7901453
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
[TBL] [Abstract][Full Text] [Related]
27. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.
Didier A; Loor F
Anticancer Drugs; 1996 Sep; 7(7):745-51. PubMed ID: 8949985
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
30. Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma.
Tong AW; Su D; Mues G; Tillery GW; Goldstein R; Klintmalm G; Stone MJ
Clin Cancer Res; 1996 Mar; 2(3):531-9. PubMed ID: 9816200
[TBL] [Abstract][Full Text] [Related]
31. Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy.
Månsson E; Paul A; Löfgren C; Ullberg K; Paul C; Eriksson S; Albertioni F
Br J Haematol; 2001 Sep; 114(3):557-65. PubMed ID: 11552980
[TBL] [Abstract][Full Text] [Related]
32. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Sonneveld P; Schoester M; de Leeuw K
J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
35. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Liminga G; Nygren P; Larsson R
Exp Cell Res; 1994 Jun; 212(2):291-6. PubMed ID: 7910563
[TBL] [Abstract][Full Text] [Related]
36. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Yano S; Sone S; Nishioka Y; Naito M; Tsuruo T; Ogura T
Jpn J Cancer Res; 1994 Feb; 85(2):194-203. PubMed ID: 7511575
[TBL] [Abstract][Full Text] [Related]
38. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
39. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Boesch D; Loor F
Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833.
Egashira M; Kawamata N; Sugimoto K; Kaneko T; Oshimi K
Blood; 1999 Jan; 93(2):599-606. PubMed ID: 9885221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
